33 results about "Bone marrow transplantation" patented technology

Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.

It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.

The invention belongs to the field of biological medicines and discloses an immunochromatography test paper technology, which is used for specifically measuring the negative, positive and titer of IgM, IgG and IgA blood group antibodies in blood or body fluid or tissue fluid or secretion of people. The technology comprises the following steps: (1) preparing a sample filter membrane and a sample pad; (2) preparing a tracer and a tracing pad; (3) preparing a fiber membrane detection area and a quality control area; (4) labeling a test strip; (5) assembling the test strip; (6) injecting a sample and detecting; and (7) reading a result. The test strip can be used for measuring IgM anti-A and anti-B antibody titer, monitoring implantation of bone marrow transplantation and measuring the titer of immune IgG anti-A and anti-B antibodies of individuals, particularly prenatal pregnant women and newborns, the reverse typing of blood groups can be accurately judged by specifically measuring the IgM anti-A and anti-B antibodies, and the reverse typing of the blood group of an individual can be judged through saliva without blood sampling by specifically measuring IgA anti-A and anti-B antibodies in secretion.

The invention is the gene engineering preparation polypeptide remedy technology field of biology technology. The aid is to build a double function fusion albumen gene of rhTPO/SCF, express and prepare with more biology activityú¼less side-effect rhTPO/SCF in insect cell. The gene of rhTPO/SCF includes 1-157 amino acids coding sequence with TPO, 16 amino acids continual peptide coding sequence, 1-145 amino acids coding sequence of SCF and codoní»s DNA fragments. By taking the rhTPO/SCF into TF1 cells experiment, which preparation from the infect recombination virus growing in adherence S19 cell, it mensurates that the specific activity is 2.0 í‡10 to the power 5 units/mg; by Mo7e cells experiment, the specific activity is 8.3í‡10 to the power 5 units/mg. It can be used to cure low blood platelet cause by radiotherapy, chemotherapy, bone marrow transplantationíú

The invention discloses a human stem cell growth factor as well as a production method and application of a polyethylene glycol (PEG) modified human stem cell growth factor. The production method comprises the following steps of: fusing an h-SCF (Stem Cell Factor)-alpha sequence and an SUMO (Small Ubiquitin-Related Modifier) sequence and constructing to obtain an SUMO-rhSCF-alpha fused gene expression vector; transferring the SUMO-rhSCF-alpha fused gene expression vector into a host bacteria to obtain engineering bacteria; culturing the engineering bacteria and inducing to express an SUMO-rhSCF-alpha fused protein; and cutting off an SUMO part to obtain an rhSCF-alpha protein. By using the production method, the high soluble expression and large-scale purification of the rhSCF-alpha protein in cell plasmas are realized, and the activity of the obtained rhSCF-alpha protein is high. The invention also discloses the production method of the PEG modified human stem cell growth factor; the half-life period of the PEG modified human stem cell growth factor obtained by using the method is remarkably prolonged, and the activity of the PEG modified human stem cell growth factor in promoting the proliferation of red blood cells is also remarkably improved; and the PEG modified human stem cell growth factor can be applied to the preparation of medicines for hypohemia therapy, reconstruction and recovery of a hematopoietic function after chemoradiotherapy and a bone marrow transplantation operation, stem cell ex-vivo expansion and gene therapy and cosmetics for promoting the metabolism of epidermal cells, repairing aged and damaged skin cells, delaying the aging of skin and the like.

The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one resistin agonist, resistin polynucleotide and/or resistin polypeptide for the prevention and/or treatment of mammalian hematopoietic disorders, including, but not limited to, anemia, leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.

A transduction peptide-humanized granulocyte colony stimulating factor fusion protein, nucleic acid molecule of nucleic acid sequence for encoding fusion protein, expression carrier containing the nucleic acid molecule and its usage of fusion protein in preparation of medicine are disclosed. It can be used for neutrophil reduction after tumor radiant chemo-radiotherapy, hematopoietic restoration after bone marrow transplantation, peripheral blood stem cells mobilization, anti-infective therapy, aregenerative anemia, systemic lupus erythematosus and immune response adjustment.

A method for quantifying the expression level of human WT1 mRNA conveniently, in a short period of time, and with high sensitivity is provided. The method can be used for diagnosing cancer, such as leukemia and solid cancer, or for determining when to perform bone marrow transplantation. The method is for quantifying the expression level of human WT1 mRNA by one-step RT-PCR and comprises simultaneously subjecting the human WT1 mRNA and a housekeeping gene (mRNA) to reverse transcription and extension reactions carried out sequentially in the same vessel.

The invention provides novel application of the acetylcysteine; the acetylcysteine is suitable for treating oral ulcer; and an acetylcysteine gel, which is prepared according to the application, simultaneously has medicinal functions of rapidly relieving pain and preventing ulcer, and specifically inhibiting further spread of ulcer in patients receiving radiotherapy, chemotherapy and bone marrow transplantation and promoting wound healing.

The invention provides a set of genotype sequences for HLA typing. The genotype sequences comprise a nucleotide sequence as shown in SEQ ID No. 1, and optionally comprise at least one of the nucleotide sequences as shown in SEQ ID No. 2-10. The genotype sequences for HLA typing of the invention enrich a HLA database, and can effectively improve typing accuracy, thereby improving the treatment efficiency of related diseases, such as thalassemia, acute leukemia and bone marrow transplantation.

The invention discloses application of dendritic cell expressed TGF-beta 1 (transforming growth factor-beta1) in preparing anti-atherosclerosis medicaments. According to the application, a mouse dendritic cell (DC) unexpressed TGF-beta1 is successfully hybridized by means of a cre-lox technology, and the bone marrow of the mouse is embedded in a susceptible mouse Apoe-/- with atherosclerosis by means of bone marrow transplantation, and the mouse is induced to generate atherosclerosis by means of high fat diet. Results discover that the DC unexpressed TGF-beta1 causes increase of total cholesterol of plasma and remarkable increase of the plaque area of atherosclerosis, and indicate that the DC expressed TGF-beta1 is capable of resisting atherosclerosis by reducing the cholesterol level of plasma; the DC expressed TGF-beta1 can be used for preparing anti-atherosclerosis medicaments based on the anti-atherosclerosis effect of the DC expressed TGF-beta1, and a novel direction is provided to development of anti-atherosclerosis medicaments.

The invention discloses application of macrophage-targeting RIPK1 and an RIPK1 inhibitor in screening and preparing a liver injury diagnosis and treatment medicine RIPK1 inactivated mouse bone marrow is transplanted into a normal C57 mouse to construct a non-alcoholic fatty liver, cirrhosis and hepatic fibrosis model, a result shows that the liver function of the mouse with transplanted RIPK1 inactivated bone marrow is obviously superior to that of a mouse with transplanted C57 mouse bone marrow, the contents of glutamic-pyruvic transaminase and triglyceride in serum are obviously reduced, a lipid component pathological staining result shows that the mouse with transplanted RIPK1 inactivated bone marrow can obviously relieve fatty liver lesion and significantly reduce lipid accumulation, and it is found that RIPK1 inactivation can significantly reduce inflammation and death of palmitic acid-induced bone marrow macrophages. A macrophage-targeting RIPK1 active site can be used as a medicine target for screening and treating liver injury diseases such as fatty liver, cirrhosis and hepatic fibrosis, and the RIPK1 inhibitor can be used for preparing the medicine for treating the liver injury diseases.

The invention discloses riboflavin derivatives, and a process of preparing the same, and their applications. The w/o suspending preparation of the riboflavin derivatives has high stability, and the effects could last for 3 months after intramuscular injection at dose of 150 mg. This invention increases significantly the bioavailability of riboflavin in vivo, and provides an important treatment method for cure of ariboflavinosis. The preparation is found to have remarkable effect on dermatitis, oral and digestive tract catarrhs caused by bone marrow transplantation for leukemia and chemotherapy for tumor. It is also found to have noticeable effect on persistent oral ulcer, and enhance the tolerability to chemotherapy and radiotherapy. In the treatment of coronary heart disease and hypertension syndrome, arthritis and burn wound, the preparation also has significant effects. This invention has a wide application perspective for its simple techniques, definite long-acting action and effectiveness.